California's GLP-1 Cost Bill, SB 1089 Explained

SB 1089 cleared both chambers of the California Legislature on August 27, 2026 with no votes against it at any stage. It has not reached the governor yet. It doesn't cap what you pay, doesn't require any insurer to cover a GLP-1, and carries no money. It authorizes the state to try to negotiate, if it chooses, and if a future legislature funds it. It does open the door for more negotiating of medication prices that could work in your favor though!

What the bill actually says

The Preventive Treatment Health Care Act amends one section of the Health and Safety Code, the statute behind the state's CalRx generic drug program. The operative language, from the bill's own summary, authorizes the state health agency to "enter into partnerships, if needed and subject to an appropriation, to increase competition, lower prices, and address supply shortages for at least one glucagon-like peptide-1 (GLP-1) antiobesity medication approved by the United States Food and Drug Administration" (bill text).

Three qualifiers in one sentence: ‘may’, ‘if needed’, and ‘subject to an appropriation’. On pricing it asks for a "best effort to negotiate" at or below what Medi-Cal paid in 2025. That's a best effort, and it isn't a required price.

Status as of today: in engrossing and enrolling. The Senate concurred in Assembly amendments 39 to 0 on August 27 and ordered it to engrossing and enrolling (legislative record). CalMatters' bill tracker still lists it as in progress (Digital Democracy).

Engrossing and enrolling is the clerical stage where staff prepare and certify the official final copy. The bill has passed both chambers, but it hasn't been enrolled, it hasn't been presented to the governor, and no signing clock has started. Once it is presented, the governor has until September 30, 2026 to act on bills passed before September 1, and if signed it takes effect January 1, 2027 (official bill status).

What changes for a Californian on January 1: nothing yet

No patient gains coverage, no copay is capped, and nothing changes on a formulary. The bill adds GLP-1s to the list of things the state is permitted to pursue under CalRx. Any actual price reduction needs a later appropriation, then a willing manufacturer, then distribution partners, then production. That's a long chain, and it hasn't started.

The timeline precedent matters here. California's CalRx insulin took about three years to reach market (CalMatters), and insulin is off patent and cheap to produce. Semaglutide and tirzepatide are on-patent brand drugs, a categorically harder problem, and nobody has yet explained publicly how the state would get one at 2025 Medi-Cal pricing.

Separately, and predating this bill, California law already requires many state-regulated plans to cover GLP-1s for diabetes and for morbid obesity at a BMI of 40 or above. That isn't changed by SB 1089.

The bill that passed is the one that was stripped down

An earlier version would have required the state employee health system, CalPERS, to cover GLP-1s from 2028. CalPERS opposed it and estimated a first-year premium increase of $437.3 million, about $28.09 per member per month, with roughly 600,000 of its 1.28 million members potentially eligible (CalPERS board agenda).

That mandate was removed before passage. Attaching those figures to the bill as it stands would be wrong, and you'll see it done anyway. What survived is the permissive CalRx authorization.

The wider pattern in the same session tells the real story. Two California bills that would have actually mandated commercial coverage of anti-obesity medication both failed. One died in January 2026 without a hearing (AB 575 record), and the other stalled in Assembly Appropriations for more than a year and missed the fiscal deadline this month (SB 535 record). The bill that made it through is the one with no mandate and no money attached, but which opens the doors to future price lowering.

Whether other states follow depends on which version they copy

If California enacts a funded CalRx partnership that actually delivers a lower price, that's a genuinely new model and other states would have reason to watch it. The insulin program is the proof of concept, though it took a while to arrive.

Similar laws aimed at reducing costs for GLP-1s in other states have not come as far. Colorado's compounded GLP-1 regulation bill passed its Senate and was then killed in committee 12 to 0 in May 2026 (Colorado legislature). State employee plans in several states expanded GLP-1 coverage and then pulled back. On the Medicaid side, KFF tracks which states still cover these drugs for weight loss, and the count has been falling (KFF).

The one place a broad low price already exists is federal rather than state. The Medicare GLP-1 Bridge runs at a $50 monthly copay through December 2027 for those who qualify (CMS). We covered what to do when a Bridge claim bounces in our piece on rejected claims.

What to watch, if you live in California

Presentation to the governor, then September 30: the bill has to finish enrolling and be presented before any deadline starts running. After that it is signature, veto, or becoming law unsigned. Given unanimous passage and no fiscal obligation, signature looks likely, though that is a judgement rather than a fact.
January 2027 budget proposal: whether a GLP-1 line item appears for CalRx. Without an appropriation the authorization sits unused, and this is the single clearest signal of whether anything real follows.
Your own plan, separately: none of this touches open enrollment decisions, and coverage changes for 2027 will come from your plan rather than from Sacramento. Our open enrollment guide has the dates.

Final Takeaway

This is a permission slip, and it isn't a price cut. It lets California try something, it commits no funds, and the two bills that would have actually required coverage in the same session both died.

That is not nothing. A state-negotiated GLP-1 would be a first, and if it works other states have a template. But the honest answer to "will this make my medication cheaper" is that it can't on its own, and the next signal is a budget line in January. In the meantime, if cost is the pressure, our provider survey matches on state and budget.

If you enjoy posts like these, you can subscribe to receive newsletter updates.